Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing
about
Long-chain acyl-CoA dehydrogenase deficiency as a cause of pulmonary surfactant dysfunctionComputational modeling to accelerate the identification of substrates and inhibitors for transporters that affect drug dispositionThe evolution of farnesoid X, vitamin D, and pregnane X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) and other non-mammalian species.Finding promiscuous old drugs for new uses.Identification of inhibitor concentrations to efficiently screen and measure inhibition Ki values against solute carrier transporters.Uptake of pramipexole by human organic cation transporters.Why we should be vigilant: drug cytotoxicity observed with in vitro transporter inhibition studies.Reliability of inhibition models to correctly identify type of inhibitionQuantitative structure activity relationship for inhibition of human organic cation/carnitine transporter.Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition.A substrate pharmacophore for the human organic cation/carnitine transporter identifies compounds associated with rhabdomyolysis.Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K.Making Transporter Models for Drug-Drug Interaction Prediction Mobile.Inhibition of OCTN2-mediated transport of carnitine by etoposide.Cisplatin-induced downregulation of OCTN2 affects carnitine wastingStructure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP)Uptake carriers and oncology drug safety.Renal Drug Transporters and Drug Interactions.A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus.Comparison of Deep Learning With Multiple Machine Learning Methods and Metrics Using Diverse Drug Discovery Data Sets.
P2860
Q28308215-A3D046FA-B70F-456B-80A4-206E1865E882Q33599159-3DE452B9-4838-489F-B2F9-CD87664218DEQ33811323-9EE3F652-E98E-4161-A075-9D64194AA94DQ33910025-B8C57115-0735-4594-8F52-93D6FF2ED015Q34017816-D89478A8-1BB1-4686-900A-7CCEFE2F9031Q34037009-FA533843-8A32-4B27-9E17-B618513A1553Q34148447-9EDCA48D-F843-4A84-8A05-CE030CAC0266Q34233658-60404EDB-F403-4D92-83F1-038CEBE180BEQ34384867-263E470E-9C6D-40DB-893D-450312F6A6C7Q35185827-3021CBC7-7A5B-4389-AC4B-A03EB5783E21Q35869583-22B70FC3-F139-4DE2-8136-182DDB0835A9Q35996683-0296856C-753E-44A2-ACD8-D97699525DE9Q36077704-E3CDB795-BB48-497C-A926-B177E8FB922CQ36302949-E2BAB7CA-E16D-407B-B1CE-2F5C0554A4B0Q36491674-C4CCF4A9-E047-4BA4-BC43-EA3041782342Q36742673-3E98E1CB-CAD7-4D7D-B5CE-E6B0F739A731Q37663396-3929A3F2-4B01-4B3B-8272-FF324398B8B8Q39140289-A8DC60C2-5F98-42F2-8B28-1BCCF66C3A57Q40170777-FC951449-00FA-43D8-87F8-CB1A71B9C8B9Q45944238-D0395447-40FA-4CAD-84C4-F8AA62B07821
P2860
Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Novel inhibitors of human orga ...... modeling and in vitro testing
@ast
Novel inhibitors of human orga ...... modeling and in vitro testing
@en
type
label
Novel inhibitors of human orga ...... modeling and in vitro testing
@ast
Novel inhibitors of human orga ...... modeling and in vitro testing
@en
prefLabel
Novel inhibitors of human orga ...... modeling and in vitro testing
@ast
Novel inhibitors of human orga ...... modeling and in vitro testing
@en
P2860
P1476
Novel inhibitors of human orga ...... modeling and in vitro testing
@en
P2093
James E Polli
P2860
P304
P356
10.1007/S11095-009-9905-3
P50
P577
2009-05-13T00:00:00Z